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Abstract
Background: Epidural administration of morphine has been shown to be an effective analgesic strategy in horses;
however, the possible occurrence of side effects limits its usage. In order to decrease their frequency, it is important
to target the minimal effective plasma concentration and avoid overdosing. As to date species-specific
pharmacokinetics data are not available for epidural morphine, the dosing regimen is usually established on the
basis of clinical reports and personal experience. In certain physiological conditions, like gestation, the outcome of
an empirical dosing scheme can be unpredictable. The aim of this case report is to describe the pharmacological
profile of morphine and its metabolites after prolonged epidural administration in a pregnant mare and her foal.
Case presentation: A 20 years old pregnant mare was presented to our hospital because of severe lameness,
2 months before delivery. Following an ineffective systemic pain treatment, an epidural catheter was inserted and
morphine administered (initial dose 0.1 mg/kg every 8 h). Due to its efficacy in controlling pain, it was continued
until end of gestation. Plasmatic concentration of morphine and its metabolites were assessed in the mare 6 weeks
after starting the treatment, and in both the mare and foal during the first days after delivery. Plasmatic values
similar to those previously reported in the literature following morphine short term administration through various
routes and not accompanied by side effects were found in the mare, except during an excitatory period. Moreover,
no evidence of dangerous drug accumulation or significant milk passage was noticed in the foal. Mild reduction of
feces production with no signs of colic and two self-limiting episodes of excitement occurred during treatment in
the mare. No side effects occurred during gestation and first phases of life in the foal.
Conclusion: Prolonged epidural administration of morphine in a pregnant mare allowed good pain control in
absence of clinically relevant side effects, in both the mare and her foal. Sudden increase in morphine plasmatic
concentration can occur and side effects appear; careful treatment to the lowest effective dose and continuous
monitoring of the clinical condition of the treated horse should be performed.
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Background
Epidural injection of morphine has been used to treat
various painful conditions in horses [1–3]. Despite good
clinical outcomes after both single and repeated injec-
tions, the risk of side effects, especially on the gastro-
intestinal system, limit its usage [4]. However, it has
recently been shown that a single dose of epidural
morphine (up to 0.1 mg/kg) does not delay gastro-
intestinal transit time [5]. Moreover, repeated epidural
administration of morphine (0.1 mg/kg every 8 h for 4
days) did not provoke any neurological or behavioural
abnormalities [3]. Finally, no changes in rectal
temperature, heart rate, respiratory rate, and gastrointes-
tinal motility were observed during prolonged epidural
administration over a period of 14 days (0.2 mg/kg of
morphine every 12 h) [6].
Morphine is primarily metabolised by the liver. The
only metabolites identified in equine blood are
morphine-3- glucuronide (M3G) and morphine-6-
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glucuronide (M6G) [7]. While M6G has been shown to
have analgesic activity [8], animal studies suggest that
M3G has no analgesic effect [9] and may antagonise the
analgesic effect of M6G and morphine [10]. Moreover, it
has been associated with neuro-excitatory behaviour in
rats [11].
When drug administration is performed in pregnant
mares, it is important to consider that drug absorbed
into the systemic circulation can reach the foetus. Val-
verde et al. (1990) [1] reported a successful repeated epi-
dural injection over three days in a pregnant mare
following digital amputation; unfortunately, no specific
information about effects on the foetus as well as no
pharmacological profile was described.
The aim of this case report is to describe the pharma-
cological profile of morphine and its metabolites after
repeated epidural injections in a pregnant mare, 6 weeks
after start of the treatment. Moreover, plasmatic concen-
trations of morphine and its metabolites in the foetus
after birth are reported.
Case presentation
A 550 Kg, 20 years old pregnant mare was presented at
the equine teaching hospital due to severe hindlimbs
lameness. A heart rate of 56 beats per minute, a respira-
tory rate of 16 breaths per minute and clear signs of pain
were present at the clinical examination. A radiological
study revealed a high-grade, chronic tendinopathy of the
suspensory branches on the right and left side. Since foal
delivery was expected within 2 months, the horse was
hospitalised for pain and supportive therapy. During the
hospitalization, pain could not be easily controlled, des-
pite the adoption of a multimodal systemic analgesic
plan. A pain score [12] was used in order to monitor the
analgesic efficacy of the attempted treatments. Due to
the inefficacy of a combination of methadone, non-
steroidal anti-inflammatory agents and gabapentin in
controlling pain over the first week, an epidural catheter
placement was planned, in order to provide repeated
morphine administrations into the epidural space. The
sacro-coccigeal area was clipped and aseptically pre-
pared, and a Tuohy needle was inserted targeting the
sacro-coccigeal space, with the needle opening pointing
cranially. The hanging drop technique with sterile saline
was used to confirm the needle tip location into the epi-
dural space. An epidural catheter was advanced through
the Tuohy needle, for a length previously calculated in
order to reach the L4-L5 vertebra. A bacterial filter was
applied to the injection port and the catheter was se-
cured to the skin with adhesive material and covered
with adhesive dressing. The systemic analgesic treatment
was stopped. An initial epidural dose of 0.1 mg/kg of
morphine (Morphin HCl Sintetica, Sintetica S.A.,
Switzerland) every 8 h was started, with immediate
improvement of the clinical condition. After each drug
injection, the epidural catheter was always flushed with a
volume of 6 ml of sterile saline. An abdominal ultra-
sound examination was repeatedly performed in order to
check the clinical condition of the foal, with no abnor-
malities detected until delivery. On day 16 (from now
on, days are reported as “days after starting the epidural
analgesic treatment”), a strong excitatory phase with in-
creased locomotor activity, dysphoria and photophobia
occurred and lasted for few hours. Even if it could not
be correlated to any particular injection or time interval
after injection, a morphine overdose was suspected. Its
administration was stopped and epidural methadone
(0.1 mg/kg) (Methadone Sintetica, Sintetica S.A.,
Switzerland) was given instead. Two days later, due to
stable clinical conditions, methadone was stopped and
morphine restarted. During the excitatory period, the
horse was moved to an isolated and quiet stable and the
windows were covered with black light-reflecting mater-
ial. On day 21, due to a weaning of the analgesic effect
of morphine within one hour before administration,
shorter intervals (6 h) were adopted and ketamine (Keta-
sol, Graeub AG, Switzerland) was added (0.1 mg/kg
every 6 h). On day 42, a second but milder excitatory
episode occurred; also in this case, it could not be corre-
lated to any particular injection or time interval after in-
jection. Morphine was interrupted for 24 h and it was
substituted by epidural methadone (0.1 mg/kg). The day
after, due to stable clinical conditions, methadone was
stopped and morphine restarted at half of the dosage.
On day 49, the foal was delivered and morphine dose
was further reduced to 0.025 mg/kg. On day 53, epidural
administration was stopped and morphine (0.025 mg/kg)
and ketamine (0.5 mg/kg) were injected intramuscularly,
every 8 h. On day 56 the epidural catheter was removed.
A bacterial examination of the catheter tip was per-
formed and no contamination was found. Finally, on day
57, the mare and the foal were discharged from the hos-
pital in stable clinical conditions and the analgesic ther-
apy of the mare was continued at home by the private
veterinarian. During the whole hospitalization period, re-
duction in faeces production occurred but no signs of
colic were noticed.
Blood sampling
After obtaining owner consent, the plasmatic levels of
morphine ant its metabolites (M3G and M6G) were
evaluated to titrate the analgesic treatment over time.
Moreover, blood samples were taken from the foal (in
concomitance with already needed blood withdrawal for
routine tests) in order to rule out morphine overdosing.
On day 36, a sequential blood sampling (SBS) from the
mare was performed, at 30 min before and 1, 3 and 5 h
after morphine administration. Another sample was
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taken on day 42, one hour and a half after morphine in-
jection, during the episode of excitation and increased
locomotor activity. Further blood samples were taken on
day 49, 50 and 51 (day of delivery and 1 and 2 days post-
delivery). For each blood collection, 10 ml of blood were
withdrawn and put aside, 10 ml were then collected in
an EDTA syringe and the previous blood administered
back to the horse. The blood was immediately centri-
fuged (3000 rotation per minute for 10 min at 20 °C) and
the plasma successively stored at − 80° in special cryo-
tube (CryoPure Tube, Sarstedt, Germany). Withdrawal
of blood from the foal was performed on day 0 (after de-
livery, before first meal), on day 1 and on day 2. In this
case, 1.5 ml of blood was taken and transferred in an
EDTA tube; then, the same centrifugation and storages
process as for the mare was applied. Measurement of
morphine, M3G and M6G plasmatic concentration were
performed using liquid chromatography-tandem mass
spectrometry. Results are presented in Tables 1 and 2.
Discussion and conclusion
Although the usefulness of epidural analgesia in horses
is well documented in the literature, only scarce infor-
mation about plasma concentrations of morphine fol-
lowing epidural administration is available.
So far, no pharmacokinetic studies about morphine
and its metabolites after repeated epidural administra-
tion have been reported in horses. Natalini (2006) [13]
investigated the plasmatic concentration of morphine
after a single epidural injection of 0.1 mg/kg in horses
and found maximum plasmatic concentration of 90 ng/
ml at 120 min post-injection; no clinical variables were
reported.
In another study, following intravenous (IV) and intra-
muscular (IM) administration of 0.05 or 0.1 mg/kg mor-
phine in horses, values higher than 8 ng/ml were found
and they were not correlated with any respiratory or be-
havioural modifications, except mild reduction of gut
sounds (with no reduction in faeces production) [4].
However, in the same study, an increase in heart rate
and blood pressure developed for approximately two mi-
nutes after IV injection, associated with morphine plas-
matic level > 150 ng/ml.
In another study in horses, behavioural responses,
such as fasciculations, sweating and increase in loco-
motor activity were noticed for about 45 min after mor-
phine IV injection at dosages of 0.2 to 0.5 mg/kg [7].
To the authors’ knowledge, no available data on mini-
mum effective plasmatic concentrations of morphine
and its metabolites in equine species are known. In the
present study, values between 6.4 and 21.9 ng/ml for
morphine, 8.3 and 14.2 ng/ml for M6G and 235.6 and
339.2 ng/ml for M3G were found during the SBS. As
successful analgesia was achieved in absence of clinically
relevant side effects, plasmatic concentrations in the re-
ported ranges could be considered as effective. More-
over, they did not exceed the level previously reported to
induce tachycardia and increase in blood pressure in
horses [7].
In the present case, when the SBC was performed,
peak plasmatic concentration of morphine and its me-
tabolites were found 1-h post injection and trough 5.5 h
post injection (30 min before the next injection).
A strong agonism of M6G to mu-receptors have been
reported [14–17]. Around 85% of the analgesic effect of
morphine is supposed to derive from the M6G [18]. In
contrast, M3G has up to 200 times lower mu-receptor
binding compared with morphine [19] and it seems to
lack analgesic activity, with some studies suggesting an
antagonist [10, 16, 20] or just a weak agonist activity
[21].
It is interesting to notice that when the blood sam-
ple was taken during the excitatory period, morphine
concentration was 69.6 ng/ml, around three times
higher than the peak plasmatic concentration found
during the SBS, while M6G and M3G were consistent
with the previously measured concentrations (10.4 ng/
ml for M6G and 164.4 ng/ml for M3G). From these
results it could be hypothesized that the high concen-
tration of morphine, rather than its metabolites, could
be the cause of the excitatory side effects, but the
reason why there was an increase in morphine and
not of its metabolites is not clear. Full blood work
was performed the same day, but no pathological
findings, especially in the liver function tests, were
found.
Table 1 Plasmatic concentration of morphine and its
metabolites in the mare (ng/ml)
Days Morphine M3G M6G
36 5.88 213.87 7.59
36 19.89 307.85 12.96
36 8.25 278.57 10.36
36 6.16 241.21 8.48
42 63.18 149.26 9.45
49 1.66 93.01 3.08
50 4.82 125.20 5.79
51 1.66 57.82 2.23
Table 2 Plasmatic concentration of morphine and its
metabolites in the foal (ng/ml)
Days (from birth) Morphine M3G M6G
0 2.40 6.71 < 0.14
1 1.48 10.13 < 0.14
2 < 0.03 3.11 < 0.14
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Up to date, there were no reports describing plasmatic
concentrations of morphine in neonatal foals born from
mares receiving long-term epidural morphine. Moreover
it is not known whether there might be a correlation be-
tween maternal morphine plasmatic concentration and
the occurrence of undesired side effects in the new born
foal. At the concentrations found in the present case, no
side effects (respiratory depression, reduced appetite,
dysphoria, among others) were seen, and no problems
were encountered until discharge from the hospital. It is
interesting to notice that plasmatic concentrations of
morphine before the first meal were slightly higher in
the foal compared to the mare, whereas plasmatic con-
centration of its metabolites were substantially higher in
the mare compared to the foal. The immature liver func-
tion could have led to accumulation of the parent drug
and reduction of its metabolization.
If the presence of morphine in the blood during the
last phase of gestation can lead to pain pathway abnor-
malities/addiction in the future is not known for horses.
In humans, neonates born from opioid dependent
women are more likely to have low weight at birth, to be
admitted to the neonatal intensive care unit and to re-
quire prolonged treatment for neonatal abstinence syn-
drome [22, 23]. The neonatal abstinence syndrome is a
drug withdrawal syndrome after birth that affects 45–
94% of infants born from opioid dependent mothers,
resulting in significant neonatal morbidity [24–26].
Sometimes it can also appear after few days from birth
[27]. Even though morphine has a low lipid solubility
compared to other opioids, its poor protein binding
favour its passage through the placenta. In the present
case, no abnormalities were noticed during the
hospitalization period and no abnormalities were re-
ported from the owner up to 3 months after birth. The
difference in placental structure between humans and
horses, as well as the different maturity at birth could
play an important role in drug transfer and effects on
the foetus.
The possible passage from the mare to the foal during
lactation should also be considered. In a case series of
women undergoing surgery during the lactation period
(at least 1 month after giving birth) receiving IV or IM
morphine, only mild and occasionally observed respira-
tory depression or drowsiness in the child occurred [28].
In another clinical study in women receiving epidural
morphine for delivery, measurable quantities in the milk
were found only in three samples within the following
36 h [29]. In the present case no analysis of the milk was
performed. However, plasmatic concentration of mor-
phine and its metabolites in the foal decreased from day
0 (before first meal) to day 2, reflecting a possible null or
minimal passage of the drug from the milk to the
neonate.
A last point to consider is that differences in plasmatic
volume during pregnancy could have led to different
plasma concentrations compared to non-pregnant
horses. Recently, a review about pharmacokinetic and
pharmacodynamics of morphine in pregnant women has
been published. Compared to non-pregnant women,
morphine in pregnant women has an unchanged volume
of distribution, a clearance > 70% and a decreased half-
life [30]. In another study, the area under the curve for
unconjugated morphine within two days after morphine
epidural injection in pregnant women was similar to
those reported for epidural administration in the non-
pregnant ones [29]. To the authors knowledge, the influ-
ence of gestation on the morphine pharmacokinetics
and pharmacodynamics in pregnant horses is not
known.
This case report presents plasmatic concentrations of
morphine and its metabolite after a long-term epidural
treatment in a pregnant mare. Results show that plas-
matic level reached over prolonged epidural administra-
tion do not exceed those previously reported to be
effective and at the same time safe for the animal. Sud-
den increase in morphine plasmatic concentration in the
mare can occur and side effect appear; careful treatment
to the lowest effective dose and continuous monitoring
of the clinical condition of the treated horse should be
performed. No clinically relevant effects on the foetus
were noticed during the whole gestation period; more-
over, the plasmatic concentrations found after birth did
not affect the essential steps during the first phases of
life.
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